about
AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 traffickingTakayasu's Arteritis with Isolated Pulmonary Artery Involvement in a Middle-Aged Asian Woman with Hepatitis B and Latent Tuberculosis Infection.Counter-regulation of T cell effector function by differentially activated p38.Identification of a novel PPARβ/δ/miR-21-3p axis in UV-induced skin inflammation.Epidermal IL-15Rα acts as an endogenous antagonist of psoriasiform inflammation in mouse and man.Severe Sweet's Syndrome with Elevated Cutaneous Interleukin-1β after Azathioprine Exposure: Case Report and Review of the Literature.Modulation of T cell responses by IL-2 and IL-2 complexes.Swiss S1 Guidelines on the Systemic Treatment of Psoriasis Vulgaris.Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.Efficacy and Survival of Systemic Psoriasis Treatments: An Analysis of the Swiss Registry SDNTT.IL-1β drives inflammatory responses to propionibacterium acnes in vitro and in vivo.Cutaneous Corynebacterium Infection Presenting with Disseminated Skin Nodules and Ulceration.Canakinumab in adults with steroid-refractory pyoderma gangrenosum.Worsening of Lymphopenia during Apremilast Treatment.Rapid Growth of Lung Nodules due to Combined Pulmonary Vasculitis, Silicoanthracosis, and Chondrocalcinosis.Clinical Disease Patterns in a Regional Swiss Cohort of 34 Pyoderma Gangrenosum Patients.TNFα and IL-17A are differentially expressed in psoriasis-like vs eczema-like drug reactions to TNFα antagonists.Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab.Comparison of pyoderma gangrenosum and Martorell hypertensive ischaemic leg ulcer in a Swiss cohort.Late presenting atypical severe combined immunodeficiency (SCID) associated with a novel missense mutation in DCLRE1C.Successful treatment of SAPHO syndrome with apremilast.Detection of Small Changes in Psoriasis Intensity with PrecisePASI.Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjectsComparing biologicals and small molecule drug therapies for chronic respiratory diseasesLow-Dose Excimer 308-nm Laser for Treatment of Lichen PlanopilarisSyphilitic PharyngitisSerum CCL13 levels in patients with systemic sclerosis and controlsSpitzoid melanoma and micrometastases in two lymph node regions: a critical situationSignificantly increased CCL5/RANTES and CCR7 mRNA levels in localized scleroderma[Scleromyxedema. A chronic progressive systemic disease]"Immune" Thrombocytopenia as Key Feature of a Novel ADA2 Deficiency Variant: Implication on Differential Diagnostics of ITP in ChildrenALIGNed on adherence: subanalysis of adherence in immune-mediated inflammatory diseases in the DACH region of the global ALIGN studyTherapy response was not altered by HLA-Cw6 status in psoriasis patients treated with secukinumab: a retrospective case seriesSevere combined immunodeficiency (SCID) presenting in childhood, with agammaglobulinemia, associated with novel compound heterozygous mutations in DCLRE1CNanoparticle-Coupled Topical Methotrexate Can Normalize Immune Responses and Induce Tissue Remodeling in PsoriasisApremilast in Treatment-Refractory Recurrent Aphthous StomatitisRecurrent Herpes Zoster Ophthalmicus in a Patient With a Novel Toll-Like Receptor 3 Variant Linked to Compromised Activation Capacity in FibroblastsIL-4 receptor engagement in human neutrophils impairs their migration and extracellular trap formationQ95508910
P50
Q24296788-30CC5310-595C-49CA-B55D-8B5B12FF91DAQ33168169-AF15561A-85A4-47F2-BDC2-C70BA382E9D7Q33702970-80BCA0C8-330B-43BA-BF23-4C63086CCF8CQ37141382-1AA718A5-DB4B-4D7A-88EF-8FBB689A78CDQ37194962-A5F7D040-852B-4C4F-BE97-D5F2E2CEDF05Q38384319-391C26A1-E23D-4A68-82AE-DC6B8B594592Q38604738-29EBCF77-FC86-49C6-886C-8F825AF58F96Q38870525-DDCB295F-AAB3-4843-8432-163EB261ED46Q39012185-DA086F36-EE3D-4349-983C-E3449905FF0CQ39026710-938F89D9-6298-48F6-A575-D2272D39DCDEQ39071077-F6EA44E3-2CA4-4AF1-9C87-2AF1CB0B5F07Q40161196-25FDAA7A-6ECC-401E-BB6B-B438A2E959D4Q40427207-F5916248-BBB4-473E-B20E-666A34233D59Q42027217-18A71B5B-AEA4-4465-94E5-E550E3C806ADQ42131430-1B121A08-39DC-4F38-9509-BFEDB0A07849Q47410269-B1B75798-BD86-497D-9561-DC9F79E8AE3AQ47612421-6889C85A-866C-4EE1-B12C-EBF822DAC62AQ48182579-8BB57ED4-CDFA-4863-B277-B3A25E883803Q48194960-E9D7CF25-B188-430B-950B-22875856B8B6Q48237500-742AF86D-DEAF-4344-BBE2-DA4EE524A732Q50072317-7A8B3EE9-889B-4DE5-A40F-D068D50824F8Q53585567-B60B0A41-BFBD-4164-BD4F-EF27631246B1Q56892402-1E5AD064-698D-4773-9392-51A82CFCAAA1Q57789437-50C2F942-EBFE-4C86-81CF-DB7F90871DA3Q58657606-CB8C9E4F-DB3A-4C97-918E-73BBEFED7A5AQ58657645-0F24B586-4C84-4F60-9B09-8BDA03063249Q83687530-775A5BA8-D278-458C-A527-3DCD30C885A2Q83852326-7CCFF580-38B1-4CAB-9681-3B7E15809B54Q84203043-BED92971-8DFC-4A2D-9E2B-88700ED505B8Q84582828-3CB6DBD6-8E98-49F1-A661-3C17D69F70F1Q88277493-683753A7-6440-444C-95AF-666EC7D0BD7AQ89585026-B201945A-5712-44B2-A956-9D2B106FC47DQ89932202-661C51AA-7818-4656-B656-30EDF9ECF59BQ90985282-D6576DFE-C2A8-4F26-B65E-08B74175E11AQ91069198-9ADDD5E1-2299-4540-A866-83E0FD39092BQ91269131-05BB526C-2A76-4096-9EF0-6CE472C05B8AQ91574476-B1E19625-9E31-447F-8562-69EFAE2F84A0Q91623128-9455C1DD-CF37-4C00-B867-5202C360886AQ95508910-EFB92741-CB7B-44DA-8895-410BCAAB609D
P50
description
researcher, ORCID id # 0000-0002-3897-4578
@en
wetenschapper
@nl
name
Antonios Kolios
@ast
Antonios Kolios
@en
Antonios Kolios
@es
Antonios Kolios
@nl
type
label
Antonios Kolios
@ast
Antonios Kolios
@en
Antonios Kolios
@es
Antonios Kolios
@nl
prefLabel
Antonios Kolios
@ast
Antonios Kolios
@en
Antonios Kolios
@es
Antonios Kolios
@nl
P106
P31
P496
0000-0002-3897-4578